Basilea Pharmaceutica - Cresemba IV formulation approved in China
Basilea has announced the approval in China of the intravenous (IV) formulation of Cresemba, the company’s antifungal drug, for treating adult...
675 Views
Basilea Pharmaceutica - Yet another milestone payment from Pfizer
Sales of Basilea’s antifungal drug, Cresemba (isavuconazole), in the Asia Pacific region have triggered a milestone payment of $1.25m from the...
664 Views
Basilea Pharmaceutica - Renewed focus on anti-infectives
In February, Basilea announced a strategic refocusing on its core anti-infective business and is exploring strategic options for its oncology...
2 Views
Basilea Pharmaceutica - Spring into a new strategy
Basilea Pharmaceutica has announced that it will in-license a pre-clinical programme of novel broad spectrum anti-fungals targeting...
4 Views
Basilea Pharmaceutica - Momentum continues
Basilea reported good momentum in H121 in all parts of the business. While total revenues declined to CHF54.2m (reflecting the phasing out of...
1.2k Views